Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
18
ASTH Quote, Financials, Valuation and Earnings
Last price:
$19.8600
Seasonality move
:
0.26%
Day range:
$19.1800 - $20.0350
52-week range:
$18.0800 - $38.0900
Dividend yield:
0%
P/E ratio:
104.53x
P/S ratio:
0.34x
P/B ratio:
1.28x
Volume:
280K
Avg. volume:
537.6K
1-year change:
-46.88%
Market cap:
$996.1M
Revenue:
$2B
EPS (TTM):
$0.19
Analysts' Opinion
-
Consensus RatingAstrana Health, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.6667, Astrana Health, Inc. has an estimated upside of 79.59% from its current price of $19.8600.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.0000 representing 100% downside risk from its current price of $19.8600.
Fair Value
-
According to the consensus of 10 analysts, Astrana Health, Inc. has 79.59% upside to fair value with a price target of $35.6667 per share.
ASTH vs. S&P 500
-
Over the past 5 trading days, Astrana Health, Inc. has overperformed the S&P 500 by 8.2% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Astrana Health, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Astrana Health, Inc. has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Astrana Health, Inc. reported revenues of $956M.
Earnings Growth
-
Astrana Health, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Astrana Health, Inc. reported earnings per share of $0.01.
Enterprise value:
1.4B
EV / Invested capital:
--
Price / LTM sales:
0.34x
EV / EBIT:
22.99x
EV / Revenue:
0.48x
PEG ratio (5yr expected):
0.78x
EV / Free cash flow:
14.43x
Price / Operating cash flow:
10.02x
Enterprise value / EBITDA:
14.23x
Gross Profit (TTM):
$259.5M
Return On Assets:
0.64%
Net Income Margin (TTM):
0.34%
Return On Equity:
1.85%
Return On Invested Capital:
0.88%
Operating Margin:
2.01%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.3B | $1.7B | $2.9B | $478.7M | $956M | |
| Gross Profit | $200.2M | $235.2M | $259.5M | $66.2M | $81.6M | |
| Operating Income | $101.1M | $84.8M | $60.9M | $28.4M | $19.2M | |
| EBITDA | $118M | $109.5M | $98.3M | $35.7M | $34.8M | |
| Diluted EPS | $0.98 | $1.30 | $0.19 | $0.33 | $0.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $427.2M | $443.6M | $476.2M | $596M | $883.6M | |
| Total Assets | $871.3M | $943.4M | $1.1B | $1.3B | $2.2B | |
| Current Liabilities | $116.8M | $156.2M | $203M | $312.9M | $629.9M | |
| Total Liabilities | $339.5M | $390.1M | $457.6M | $778.3M | $1.7B | |
| Total Equity | $531.8M | $553.3M | $615.6M | $507.1M | $554.7M | |
| Total Debt | $197.2M | $219.9M | $232.1M | $470.6M | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $133.9M | $82.4M | $106.5M | $34M | $10M | |
| Cash From Investing | -$41.3M | -$170.4M | -$571.3M | -$8.1M | -$534.5M | |
| Cash From Financing | -$2.3M | $162.3M | $580.4M | -$3.2M | $648.5M | |
| Free Cash Flow | $111.5M | $69.9M | $97M | $31.7M | $7.4M | |
ASTH
Sector
Market Cap
$996.1M
$25.5M
Price % of 52-Week High
52.14%
49.47%
Dividend Yield
0%
0%
Shareholder Yield
-8.76%
-1.77%
1-Year Price Total Return
-46.88%
-21.96%
Beta (5-Year)
0.904
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$19.1925
200-day SMA
Sell
Level
$26.1688
Bollinger Bands (100)
Sell
Level
21.2474 - 30.0074
Chaikin Money Flow
Sell
Level
-5.4M
20-day SMA
Sell
Level
$21.1790
Relative Strength Index (RSI14)
Sell
Level
39.8181
ADX Line
Sell
Level
36.8318
Williams %R
Neutral
Level
-63.5619
50-day SMA
Sell
Level
$23.6512
MACD (12, 26)
Sell
Level
-1.5404
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
31.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2755)
Buy
CA Score
(Annual)
Level (0.8846)
Sell
Beneish M-Score
(Annual)
Level (-1.6711)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.8036)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Astrana Health, Inc. is a physician-centric, technology-powered, risk-bearing healthcare management company. It operates as an integrated healthcare delivery platform, providing services like Primary Care, Multi-Specialty Care, Immediate Care, Radiology, and Laboratory. The company was founded by Kenneth Sin and Thomas S. Lam in 1985 and is headquartered in Alhambra, CA.
Stock Forecast FAQ
In the current month, ASTH has received 8 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ASTH average analyst price target in the past 3 months is $35.6667.
-
Where Will Astrana Health, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Astrana Health, Inc. share price will rise to $35.6667 per share over the next 12 months.
-
What Do Analysts Say About Astrana Health, Inc.?
Analysts are divided on their view about Astrana Health, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Astrana Health, Inc. is a Sell and believe this share price will drop from its current level to $26.0000.
-
What Is Astrana Health, Inc.'s Price Target?
The price target for Astrana Health, Inc. over the next 1-year time period is forecast to be $35.6667 according to 10 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ASTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Astrana Health, Inc. is a Buy. 8 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ASTH?
You can purchase shares of Astrana Health, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Astrana Health, Inc. shares.
-
What Is The Astrana Health, Inc. Share Price Today?
Astrana Health, Inc. was last trading at $19.8600 per share. This represents the most recent stock quote for Astrana Health, Inc.. Yesterday, Astrana Health, Inc. closed at $19.8600 per share.
-
How To Buy Astrana Health, Inc. Stock Online?
In order to purchase Astrana Health, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ASTH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ASTH
Sector
P/E ratio
104.53x
23.41x
PEG ratio
0.78x
-0.01x
P/B ratio
1.28x
1.78x
Price / LTM sales
0.34x
1.56x
Growth Metrics
ASTH
Sector
Revenue growth
99.71%
3.51%
Earnings growth
-97.75%
9.95%
Revenue (5-year growth)
29.41%
6.45%
Earnings forecast
$0.33
-$0.19
Profitability
ASTH
Sector
Profitability FY 2024
$243.5M
$2.6M
Return on invested capital
0.88%
-33.25%
Return on assets
0.64%
-29.68%
Return on equity
1.85%
-38.71%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
5
Balance Sheet
ASTH
Sector
Total cash
$463.4M
$25M
Short term investments
$2.4M
$24M
Total assets
$1.4B
$71.9M
Long term debt
$1.1B
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
